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Background & Aims: Intestinal adaptation in short bowel
syndrome (SBS) consists of increased epithelial cell (EC)
proliferation as well as apoptosis. Previous microarray
analyses of intraepithelial lymphocytes (IEL) gene ex-
pression after SBS showed an increased expression of
angiotensin converting enzyme (ACE). Because ACE has
been shown to promote alveolar EC apoptosis, we ex-
amined if IEL-derived ACE plays a role in intestinal EC
apoptosis.
Methods: Mice underwent either a 70% mid-intestinal
resection (SBS group) or a transection (Sham group) and
were studied at 7 days. ACE expression was measured,
and ACE inhibition (ACE-I, enalaprilat) was used to as-
sess ACE function.
Results: IEL-derived ACE was significantly elevated in
SBS mice. The addition of an ACE-I to SBS mice resulted
in a significant decline in EC apoptosis. To address a
possible mechanism, tumor necrosis factor alpha (TNF-
α) mRNA expression was measured. TNF-α was signifi-
cantly increased in SBS mice, and decreased with ACE-I.
Interestingly, ACE-I was not able to decrease EC apopto-
sis in TNF-α knockout mice.
Conclusions: This study shows a previously unde-
scribed expression of ACE by IEL. SBS was associated
with an increase in IEL-derived ACE. ACE appears to be
associated with an up-regulation of intestinal EC apopto-
sis. ACE-I significantly decreased EC apoptosis.
Keywords: angiotensin converting enzyme; apoptosis; epithe-
lial cells; intraepithelial lymphocytes; tumor necrosis factor al-
pha.
Introduction
Short bowel syndrome (SBS) after a massive small bowel
resection results in a series of adaptive processes.1–3 A
number of growth factors and nutrients may help to
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mediate these changes.1,4–7 In addition to an increase in
functional absorption, adaptation also consists of an in-
crease in villus length and crypt depth, and an increased
number of microvilli. This adaptation requires a remod-
eling of the crypt-villus complex and includes signifi-
cant increases in both epithelial cell (EC) proliferation as
well as EC apoptosis.8–10 The regulation of gastrointesti-
nal adaptation is complex and the precise factors which
guide this adaptive process remain unclear.11 A num-
ber of local and distant trophic factors contribute to this
adaptation.5,12–15 Intraepithelial lymphocytes (IEL) also
have a role in this adaptive process. The gamma delta
T-cell receptor sub-population of the IEL, as an example,
express the trophic molecule keratinocyte growth factor
(KGF), which is up-regulated during intestinal mucosal
injury,16 and following massive small bowel resection.17
To further elucidate the relationship between IEL and the
homeostasis of the intestinal epithelium, and to identify
IEL-derived factors contributing to structural intestinal
adaptation in SBS, IEL-gene analysis (microarray assays)
were performed 1 week after massive small bowel re-
section using a mouse model. The focus of analysis was
on genes which have a role in affecting EC prolifera-
tion or apoptosis pathways. A detailed analysis of these
findings has been previously reported.18 In this previ-
ous report, IEL-derived expression of angiotensin con-
verting enzyme (ACE) was examined, as it was found
to be significantly elevated after SBS creation. Interest-
ingly, ACE has been shown to have a significant role
in promoting apoptosis in a number of organs includ-
ing pulmonary alveolar epithelial cells,19 renal epithelial
cells20 and cardiac myocytes.21 ACE has been previously
detected in the mucosal epithelium in human, swine,
rat, as well as mouse intestine18,22–27; however, whether
ACE has a functional role in mediating EC apoptosis
in the gastrointestinal mucosa has not been evaluated.
This study was designed to confirm the expression of
ACE and understand its role in small bowel during EC
turnover.
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Methods
Animals
Male, 2 month old, C57BL/6J mice (Jackson Laboratories,
Bar Harbor, ME) were maintained in a 12-h day-night
rhythm at 23◦C and a relative humidity of 40–60%.
Twenty four hours before surgery chow was exchanged
to micro-stabilized rodent liquid diet (TestDiet, Rich-
mond, IN). Anesthesia was achieved using an injection of
ketamine (87 mg/kg) and rompun (13 mg/kg) given to-
gether intramuscularly. For some experiments B6;129S6-
Tnftm1GklP(TNF-α-knockout mice, Jackson Labs) were
used. Experiments were approved by the University Com-
mittee on Use and Care of Animals at the University of
Michigan.
Animal model
Short bowel syndrome (SBS) model. A 70% mid-small
bowel resection was performed similar to that previously
described.28 This consisted of a resection of the bowel be-
tween 3.5 cm distal to the ligament of Treitz and 3.5 cm
proximal to the ileocecal valve, and was followed by an
end-to-end jejuno-ileal anastomosis with 8–0 absorbable
suture (Vicryl, Ethicon Corporation, USA).
Sham operation. Mid-small bowel was transected and re-
anastomosed without bowel resection.
Post-surgical care. Postoperatively a subcutaneous bolus of
3 ml 0.9% saline solution was given to both groups in
order to maintain hydration status. Mice were allowed ad
libitum water and liquid diet after surgery.28 Mice were
sacrificed using CO2 at 7 days post-surgery, and the in-
testine was harvested.
Treatment with ACE inhibitor. The ACE inhibitor (ACE-
I) enalaprilat, (0.6 mg/kg/day i.p. Abbott Laboratories,
North Chicago, IL) was given to a separate group of Sham
and SBS mice; starting one day prior to the surgery. In
some experiments, mice were matched to a control group
of non-operated mice; and were studied after a 7 day
period.
Histology. A 0.5 cm segment of mid-small bowel (at least
2 cm away from the anastomosis) was fixed in 10%
formaldehyde, and processed for hematoxylin and eosin
staining. Villus height and crypt depth were measured us-
ing a calibrated micrometer. Each measurement consisted
of a mean of 16 different low power fields.
Epithelial cell apoptosis assays. TUNEL staining was used
for EC apoptosis assays. Briefly, paraffin-embedded tis-
sue was assayed with TUNEL (Terminal deoxynucleotidyl
transferase Biotin-dUTP Nick End Labeling) staining, ac-
cording to manufacturer’s instructions (ApopTag InSitu
Apoptosis Detection Kit, Serological Corporation, Nor-
cross, GA), with slight modification. Slides were incu-
bated with only one-third of the recommended concen-
tration of TdT enzyme, in order to avoid over-staining.
Apoptosis rate (percent of EC showing apoptosis) was
assessed with TUNEL staining and by morphological cri-
teria (nuclear margination, chromatin and cytoplasmic
condensation, shrinkage from neighboring cells, and for-
mation of apoptotic bodies with nuclear and cytoplasmic
fragmentation).29 Each assessment of apoptosis consisted
of the mean of a minimum of 16 different crypt-villus-
complexes per animal, and a minimum of 5 animals per
experimental set. Scoring of apoptosis was similar to that
described by Marshman et al.30 A Nikon TS-100 micro-
scope was used at 400× power, and images were digitally
recorded with an Evolution MP 5.1 CCD camera. Sections
were selected that were completely longitudinal along the
crypt/villus axis. In general, expression of EC apoptosis is
referred to as the total number of apoptotic cells along this
axis per 100 EC. In some cases a more detailed analysis
of the location of apoptosis was performed using previ-
ously established techniques.30 For this, apoptosis along
the villi were differentiated between the lower one-third
of the villi and upper one-third of the villi. Apoptosis was
recorded as the number of apoptotic cells per 100 EC. For
apoptosis in the crypts, cells in each crypt were numbered
starting at the base of the crypt column, and the number
of apoptotic cells at each position was recorded as a ratio
of all counted cells at this position.30
Epithelial cell proliferation. Mice were injected intraperi-
toneally with 5-bromo-2-deoxyuridine (BrdU, 50 mg/kg,
Roche Diagnostic Corporation, IN) 1 h before mice were
sacrificed. Paraffin-embedded sections of 5 µm thickness
were deparaffinized with xylene. Immunohistochemistry
was done by using a BrdU In-Situ detection Kit ac-
cording manufacturer’s guidlines (BD PharMingen, San
Diego, CA). Briefly, endogenous peroxidase was quenched
with 3% H2O2. Slides were then incubated with biotiny-
lated anti-BrdU antibody in a 1:10 dilution, washed and
then incubated with Streptavidin-horse radish peroxidase.
Slides were then exposed to DBA substrate and counter-
stained with hematoxylin. An index of the crypt cell pro-
liferation rate was calculated by the ratio of the number
of crypt cells incorporating BrdU to the total number of
crypt cells. The total number of proliferating cells per
crypt was defined as a mean of proliferating cells in 10
crypts (counted at 45× magnification).
Mucosal cell isolation. Isolation of mucosal cells was per-
formed using a previously described protocol.31 This in-
cluded isolation of cells with an extraction buffer (1 mM
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EDTA, 1 mM dithiotheritol in phosphate buffer saline),
and purification in 30% isotonic Percoll (Pharmacia, Pis-
cataway, NJ). Viability exceeded 95% using trypan blue
exclusion staining.
IEL purification. Isolation of purified IEL from mucosal
cell isolates was performed by direct magnetic separation.
This allowed the detection of mRNA changes in a pu-
rified IEL population. Magnetic beads conjugated with
antibody to CD45 (pan-lymphoid marker) were used to
segregate IEL from EC (BioMag SelectaPure Anti-Mouse
CD 45R Antibody Particles, Polyscience Inc., Warring-
ton, PA). Magnetic separation was performed twice to
further deplete EC. Final IEL purity was greater than
99% by flow cytometry.
IEL staining and sorting. IEL were stained with antibodies
to T-cell receptor (TCR)-αβ(H57, Invitrogen Corpora-
tion Life Technologies, Carlsbad, CA), TCR-γ δ (GL3,
Invitrogen), CD4 (RM4-5, BD PharMingen, San Diego,
CA) or CD8α (53-6.7, PharMingen). Isotype control an-
tibodies were used to adjust gating. IEL sub-populations
were sorted using an EPICS Elite (Coulter, Miami,
Florida) flow cytometer. Sorted IEL were kept at 4◦C
until RNA isolation.
Isolation of total RNA. A guanidine isothio-
cyanate/chloroform extraction method was performed
using Trizol (Gibco BRL, Gaithersburg, MD) according
to manufacturer’s directions.
Reverse transcriptase polymerase chain reaction (RT-PCR).
mRNA (poly-A positive) was reversed transcribed into
cDNA following a standard protocol.31 Specific primers
for selected gene sequences were designed using pro-
prietary software (LaserGene, DNAStar, Inc, Madison,
WI). PCR and gel were run under standard conditions.32
To ensure that DNA product was generated at the ex-
ponential portion of the product curve 28 cycles were
used for somatic ACE, 32 cycles for TNF-α; and 34
cycles for angiotensin II receptors. Gel bands were an-
alyzed by DNA sequencing to ensure the correct prod-
uct. Kodak EDAS System (Rochester, NY) was used for
imaging and quantification. Results were expressed as
the ratio of the investigated mRNA over β-actin mRNA
expression.
Real-time PCR. Real-time PCR was run to better quan-
tify actual changes in ACE expression. cDNA was also
used for real time PCR. The same primers for somatic
ACE and β-actin were used as for conventional PCR,
SYBR Green I was utilized for fluorescence. PCR was run
with the following steps: 94◦C for 15 s, 66◦C for 15 s,
and 72◦C for 25 s. A cDNA standard curve was created
with defined concentrations of cDNA. This allowed for
an extrapolation of the numbers of copies using the fol-
lowing formula: cDNA copies/ml = DNA concentration
(mg/ml) × (106 pg/mg) × (pmol/660 pg) × (1/sequence
size [bp]) × (1012 mol/103 ml) × 6.023 × 1023. Ct-
values of ACE and β-actin were converted to numbers of
cDNA copies, and results expressed as the ratio of ACE
over β-actin expression.
Immunoblot analysis. Protein was extracted from isolated
IEL, and immunoblots performed using a Bio-Rad protein
assay kit (Bio-Rad Laboratories, Hercules, CA) with stan-
dard methods.33 Purified biotinylated anti-mouse ACE
(R&D Systems, Inc., Mineapolis, MN) (at a concentra-
tion of 0.1 µg/ml diluted in blocking solution (Zymed
Laboratories, Inc., San Francisco, CA) was used for ACE
detection. This was followed by an application of horse
radish peroxidase-streptavidin conjugate (1:5000 dilu-
tion; Zymed). Expression for β-actin was determined in
the same fashion by re-probing membranes with pu-
rified anti-mouse β-actin (1:8000, Sigma-Aldrich, St.
Louis, MO). The peroxidase-conjugated second antibody
is goat anti-mouse IgG (1:5000 in blocking solution)
from Santa Cruz Biotechology (Santa Cruz, CA). Results
are expressed as the ratio of ACE over β-actin protein
expression.
Statistical analysis. Data are expressed as mean ± standard
deviation. These results were analyzed using ANOVA
with least significant difference testing for post-hoc anal-
ysis of significance. For assessment of changes in apoptosis
between crypt cells using an apoptotic index, a Fisher Ex-
act test was used. Statistical significance was set at P <
0.05.
Results
Changes in ACE expression after bowel resection
Increased ACE expression after bowel resection. To confirm
previous microarray observations, IEL-derived ACE ex-
pression was measured after bowel resection using both
real-time PCR and Western blot. Real-time PCR showed
a significantly increased expression of IEL-derived ACE
mRNA in the SBS group when compared to the Sham
group (P < 0.05, N = 5) (Figure 1). Western im-
munoblotting showed a 24% increase in the SBS (2.07
± 0.59) group, and was significantly (P < 0.05) higher
than the Sham (1.69 ± 0.14) group (Figure 2).
Changes of ACE expression in IEL sub-populations. Because
of the unique phenotype of the IEL, cells were sorted by
phenotype markers. This allowed a detailed examination
of the specific subpopulations of the IEL that expressed
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Figure 1. ACE mRNA expression: mRNA expression of angiotensin converting enzyme (ACE) by real-time polymerase chain reaction
techniques. Results are the number of ACE-cDNA copies over β-actin-cDNA copies (mean ± SD, data from at least 5 mice per group).
Abbreviations: ACE-I: angiotensin converting enzyme inhibitor; SBS: short bowel syndrome. ∗P < 0.05 Sham vs. SBS.
Figure 2. ACE protein expression: Western immunoblots from
a representative mouse in the Sham (Control) and SBS groups.
Both ACE (at 160 KDa) and beta actin (β-actin, 40 KDa), used as
a control, are shown.
or did not express ACE, and the differential expression of
ACE in IEL sub-population after bowel resection. mRNA
expression of ACE was detected in all sorted IEL sub-
populations (Table 1). Although a greater expression of
ACE was noted in the CD8α sub-population, no statisti-
cal difference was noted among groups.




αβ-TCR 0.63 ± 0.01
γδ-TCR 0.57 ± 0.15
CD4 0.77 ± 0.13
CD8α 0.86 ± 0.13
IEL were derived from adult, untreated mice, and were purified
using flow cytometric sorting. Note the fairly uniform expression of
ACE in each sub-population. Abbreviations: TCR, T-cell receptor.
Data is derived from semi-quantitative PCR based on the relative
expression of beta actin, and is a mean (±SD) of IEL derived from
3 individual sortings.
Effects of ACE inhibition on small intestine
To understand the significance of increased ACE expres-
sion on SBS adaptive changes, the ACE inhibitor (ACE-I)
enalaprilat was given to a separate group of Sham and
SBS mice. These mice were matched to a control group
of untreated mice, and were studied after a 7 day period.
Weight changes in the SBS model. All groups of mice showed
some degree of weight loss following surgery; however,
the loss in each of these plateaued by the latter two days of
the study period. Pre-operative weights in the Sham, SBS
and SBS + ACE-I groups were (grams): 25.5 ± 1.3, 25.0
± 1.5 and 24.1 ± 1.2, respectively. One week following
surgery, weights were (grams): 24.2 ± 2.6, 20.8 ± 1.7,
and 21.6 ± 1.7, respectively; and represented a −4.7%,
−16.5% and a −10.7% weight loss, respectively. The
loss of weight in the SBS group was significantly greater
than the Sham or SBS+ACE-I groups (p = 0.001 and P
= 0.01, respectively); however, the loss of weight in the
1308 Apoptosis · Vol 10 · No 6 · 2005
IEL-derived ACE modulates intestinal EC apoptosis
Figure 3. Crypt cell apoptosis: Cell positional distribution of apoptosis in small intestinal crypts from mice in each treatment group.
The first cell position is at the base of the crypt, and apoptosis is reported as an index of apoptotic cells to non-apoptotic cells found
in that cell position. A minimum of 10 half-crypts (one side of a crypt) were counted per animal, and at least 5 animals for each study
group were assessed. ∗P < 0.05 comparing the two groups of mice. (A) Apoptotic index is shown for the short bowel syndrome (SBS)
group with or without angiotensin converting enzyme inhibitor (ACE-I) treatment. (B) Apoptotic index is shown for the Sham treated
(transection without resection) and non-operated mouse groups.
SBS + ACE-I group was not significantly different than
the Sham operated group (P = 0.07).
ACE-I administration significantly altered mucosal structural
adaptation. Bowel adaptation in the SBS model: Bowel
resection (i.e., the SBS model) led to significant intestinal
hypertrophy (Table 2). The villus height was noted to sig-
nificantly increase in the SBS group when compared with
the Sham group. The crypt depth increased significantly
after bowel resection (P=0.04).
Alteration of adaptation with ACE-I: ACE-I adminis-
tration led to a further increase in this intestinal hyper-
trophy (Table 2). ACE-I administration to SBS mice (SBS
+ ACE-I) resulted in a significant (P = 0.02), additional,
increase in crypt depth beyond that seen in untreated
SBS mice. Villus height was unchanged compared to the
untreated SBS group. Those mice undergoing a sham re-
section and treated with ACE-I (Sham + ACE-I) showed
no significant alteration in histological features in either
crypt depth or villus height when compared with the
Sham group.
ACE-I significantly decreased SBS-associated apoptosis.
Changes in EC apoptosis with surgical manipulation:
Rates of EC apoptosis significantly increased in both the
Sham and SBS groups compared to non-operated mice
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1.6 ± 0.7 310 ± 42 93 ± 18
Sham 2.7 ± 1.0 353 ± 40 77 ± 10
Sham + ACE-I 1.9 ± 0.4† 340 ± 20 87 ± 6
SBS 4.3 ± 1.3∗ 556 ± 66∗ 113 ± 14∗
SBS + ACE-I 1.8 ± 0.5‡ 552 ± 56∗ 145 ± 22‡
Summary (mean ± SD, from at least 6 mice per group) of results
of ACE-inhibitor (ACE-I) studies. Sham + ACE-I was used as an
additional control to assess the effects of ACE-I in the absence of
a SBS. aResults of TUNEL analysis (number of apoptotic cells per
100 epithelial cells). Abbreviations: ACE-I angiotensin converting
enzyme inhibitor; EC, epithelial cells. ∗P < 0.05 sham vs. SBS;
†P < 0.05 Sham vs. Sham + ACE-I;‡P < 0.05 SBS vs. SBS +
ACE-I.
(Figures 3 and 4, and Table 2). Rates of apoptosis were
highest in the SBS group (Table 2), however, both forms
of surgical manipulation (Sham and SBS groups) led to
increases in EC apoptosis compared to non-operated mice.
Apoptosis was increased both in the crypt (Figure 3) as
well as the villi (Figure 4).
Alteration of EC apoptosis with ACE-I: Because of the
known action of ACE-I on apoptosis in the cardiac and
pulmonary systems, intestinal EC apoptosis was examined
by using ACE-I. ACE-I resulted in a significant decline
in EC apoptosis rates was observed in both the Sham
and SBS groups. EC apoptosis decreased 2.4-fold when
compared with the untreated SBS group (Table 2). These
levels declined to those similar to that observed in non-
operated mice (Table 2). The action of ACE-I on lowering
the rate of EC apoptosis varied with the location along
the crypt-villus axis. A significant decline in the rate of
apoptosis was noted in both the crypt and lower one-third
of the intestinal villi (Figures 3 and 4). Whereas, only a
slight decline in EC apoptosis was noted with ACE-I in
the distal one-third of the intestinal villi (Figures 3 and
4).
ACE-I administration significantly increased epithelial cell pro-
liferation. To better understand the implications of ACE-I
administration on the adaptation of ECs during the early
stages of SBS, EC proliferation was assessed with BrdU
incorporation. EC proliferation was much greater (P <
0.01) in SBS mice (0.24 ± 0.07) compared to the Sham
group (0.12 ± 0.02 (number of crypt cells incorporating
BrdU to the total number of crypt cells)). Administration
of ACE-I led to a significant (P < 0.001) increase in EC
proliferation in SBS mice (0.39 ± 0.06) compared to SBS
mice which did not receive ACE-I (0.24 ± 0.07).
ACE-I administration significantly increased ACE expression.
Administration of ACE-I led to a significant increase in
both IEL-derived ACE mRNA expression in both Sham
(0.66 ± 0.22) and SBS (0.63 ± 0.25) groups of treated
mice as compared to untreated Sham and non-operated
mice (P < 0.05, P < 0.01, respectively, see Figure 1).
There was a 24% increase in ACE mRNA expression
between SBS and SBS+ACE-I groups, but the difference
was not significant.
Mechanism of ACE-mediated EC apoptosis
Alteration in angiotensin II receptor expression. ACE is me-
diated via angiotensin II (ANG II) via type 1 (subtypes
1a and 1b) and type 2 receptors.21 To address an ANG
Figure 4. Villus apoptosis: Apoptotic rate (number of apoptotic cells per 100 epithelial cells) is shown for the experimental groups.
Data is from a minimum of 5 mice in each group, and at least 10 villi from each mouse. Left portion of the graph: Data from the lower
one-third of the villi, ∗P < 0.05 Sham vs. Sham + ACE-I, and SBS group vs. SBS + ACE-I. ∗∗P < 0.01 Non-operated mice compared
to Sham operated and SBS mice. Right portion of the graph: Data from the upper one-third of the villi.‡P < 0.05 Non-operated mice vs.
SBS and Sham groups. ACE-I resulted in a reduction in apoptosis for the SBS and Sham groups, but this was not significant (P = 0.15).
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Figure 5. IEL Cytokine expression: Cytokine modulation of intraepithelial lymphocytes (IEL) 1 week postoperatively in Sham, SBS and
SBS+ACE-I groups. Intensity of mRNA expression is given as the relative value compared to beta actin expression. Of note, TNF-α
showed a significant rise in mRNA expression in the SBS group compared to Sham levels. SBS mice treated with ACE-I showed a
decline in TNF-α mRNA to Sham levels. A small decline in IL-1a was also noted, but this was not significant. ∗P < 0.01 Sham vs. SBS,
and P < 0.05 for SBS vs. SBS + ACE-I. INF-γ, interferon-gamma.












Sham 0.13 ± 0.14 0.14 ± 0.17 0.41 ± 0.19
SBS 0.05 ± 0.05 0.14 ± 0.03 0.44 ± 0.09
SBS + ACE-I 0.03 ± 0.03 0.03 ± 0.03† 0.30 ± 0.20∗
Expression of the ANGII receptor type 1b and 2 were significantly
decreased with administration of ACE-I (P < 0.05 for SBS vs. SBS
+ ACE-I). Data are from semi-quantitative RT-PCR based on the
relative expression of the target gene to beta actin expression
(mean ± SD, N = 6). ∗P < 0.05 for SBS + ACE-I group vs. SBS
group. †P = 0.001 for SBS + ACE-I group vs. SBS group.
II-mediated mechanism of ACE and/or ACE-I on EC
apoptosis, EC mRNA expression of type 1a, type 1b and
type 2 ANG II receptors were measured (Table 3). For
this purpose 3 groups of mice were investigated, Sham,
SBS and SBS + ACE-I. ANG II receptor type 2 expres-
sion decreased significantly with administration of ACE-I
(P < 0.05 SBS vs. SBS + ACE-I). No significant differ-
ence in mRNA expression was found between untreated
Sham and SBS mice. ANG II receptor type 1a mRNA
expression showed a decrease in the SBS + ACE-I group
compared to the other groups; however, this difference did
not approach significance. Type 1b receptor significantly
decreased (P = 0.01) with ACE-I treatment in SBS mice
compared to untreated SBS mice. No significant differ-
ence in mRNA expression was found between untreated
Sham and SBS mice.
Alteration of pro-inflammatory cytokine gene expression. Be-
cause ACE-I may decrease apoptosis in the cardio-
pulmonary system via a down-regulation of pro-
inflammatory cytokine expression,34,35 a similar mech-
anism was examined in the intestinal mucosa. To address
this, expression of mRNA from a number of potential
pro-inflammatory cytokines were examined: IL-1a, IL-6,
IL-12a and 12b, tumor necrosis factor alpha (TNF-α) and
interferon gamma (Figure 5). Three groups were studied:
Sham, SBS and SBS + ACE-I. Of note, TNF-α showed
a significant rise in mRNA expression in the SBS group
(0.70 ± 0.19) compared to Sham levels (0.41 ± 0.13,
P < 0.01). SBS mice treated with ACE-I showed a sig-
nificant decline in TNF-α mRNA (0.51 ± 0.07, P <
0.05) compared to untreated SBS mice; and levels were
not significantly different than Sham levels. A small de-
cline in interferon-gamma was also noted, but this was
not significant.
TNF-α and ACE-mediated EC apoptosis. The increase in
TNF-α in SBS mice, and the observed decline in TNF- α
expression with ACE-I treatment suggested this pathway
may be needed for ACE-I to mediate its blockade of EC
apoptosis. To further evaluate the mechanism by which
ACE-I treatment blocks EC apoptosis, TNF-α-knockout
(TNF-α−/−) mice were used. For this, a series of Sham
operated mice (intestinal transection and re-anastomosis
of the mid-small bowel) were studied in this section. This
model was used as TNF-α−/− mice were less tolerant of
major bowel resections, yet increased levels of EC apop-
tosis were still observed in Sham mice. Two groups of
mice were investigated: (1) Sham operated TNF-α−/−
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Table 4. Fas and Fas ligand mRNA expression
Group Fas FasL
Sham 0.96 ± 0.08 0.36 ± 0.25
SBS 1.12 ± 0.13 0.24 ± 0.20
SBS + ACE-I 1.00 ± 0.17 0.24 ± 0.11
Data shown are Fas and Fas ligand mRNA expression. Fas is ex-
pressed by epithelial cells and FasL is expressed by intraepithelial
lymphocytes. Note there was a slight increase in Fas in the SBS
group, and a decline with ACE-I treatment. This approached, but
did not reach significance (P = 0.07). FasL expression did not
appreciably change in any of the groups. Data (mean ± SD, N =
6 per group) are from semi-quantitative RT-PCR analysis based
on the relative expression of beta actin.
mice; and (2) Sham operated TNF-α−/− mice treated
with ACE-I. Rates of apoptosis in all TNF-α−/− mice
were consistently lower that wild-type mice (compare to
Table 2). Interestingly, we found that ACE-I adminis-
tration had no effect on the EC apoptosis in TNF-α−/−
mice. Rates of apoptosis were determined in each group.
Sham TNF-α−/− mice treated with ACE-I showed an EC
apoptotic rate of 1.7 ± 0.3% with TUNEL assay. Sham
TNF-α−/− mice which did not receive ACE-I had an EC
apoptotic rate of 1.8 ± 0.3% with TUNEL staining (P
> 0.05). This suggests that the presence of TNF-α was
essential for ACE-mediation of EC apoptosis.
Alteration of Fas and Fas ligand expression. Based on cardio-
pulmonary literature, Fas and Fas ligand (FasL) have
been suggested to mediate ACE apoptotic actions.35 EC
mRNA expression of Fas and IEL mRNA expression of
FasL were measured (using magnetic bead isolation, Ta-
ble 4). EC-derived Fas-expression increased slightly (but
not significantly) in SBS mice (1.12 ± 0.13) compared
to Sham mice (0.96 ± 0.08). The expression of Fas de-
creased with ACE-I treatment in SBS mice (Table 4), but
the decline was also not significant. IEL-derived FasL did
not significantly change between Sham; SBS; and SBS +
ACE-I groups.
Discussion
In this study, several novel findings are reported (summa-
rized in Table 5). First, the increase in IEL-derived ACE
expression after formation of SBS was confirmed with both
real-time PCR and Western immunoblots. Additionally,
ACE expression was found in all four major T-lymphocyte
IEL sub-populations: αβ-TCR+ and γ δ-TCR+, as well as
both CD4+ and CD8+ IEL. This increase in IEL-derived
ACE may be associated with an up-regulation of intesti-
nal EC apoptosis after bowel resection. ACE-I was used
to assess the functional role of ACE in the mucosa. We
observed that the administration of ACE-I significantly
decreased EC apoptosis. Additionally, the finding that
Table 5. Summary of the major findings of ACE-I action after
SBS formation
Parameter studied after formation of SBS Action of ACE-I
Crypt-villus architecture Increased crypt
depth
Epithelial cell apoptosis Decreased
Epithelial cell apoptosis in TNF-α knockout
mice
No effect
Epithelial cell proliferation Increased
ACE expression Increased
ACE-I was ineffective in reducing EC apoptosis in TNF-
α knockout mice suggests that TNF-α may be involved
in this ACE-mediated EC apoptosis.
ACE has been identified as a membrane-bound enzyme
(peptidyl dipeptidase) in several immunologic cells, in-
cluding lymphocytes and macrophages. T-lymphocytes
have been shown to contain high levels of ACE, ap-
proximately 28 times more per cell than monocytes.36
High levels of ACE have also been found along the in-
testinal mucosa in human, swine, rat, as well as mouse
intestine.22–27 Immunohistochemical studies23,25 have
shown that there is strong expression of ACE identified
in non-vascular sites of human and mouse intestinal mu-
cosa; however, ACE expression has not been previously
described in the IEL. ACE protein is located on the mi-
crovillus surface of the epithelium, and notably on the
luminal surface of the small intestine. Despite this well-
appreciated presence of ACE within the gastrointestinal
mucosa—the functional role of the renal angiotensin sys-
tem in the intestinal mucosa has not been well defined.
ACE has been recently found to mediate the induction of
alveolar EC apoptosis.19,37 Administration of ACE-I has
led to reduced apoptotic rates in alveolar EC, renal EC
and cardiac myocytes.20,35,38 Such action may have great
importance in preservation of the function of these organs
in a number of disease processes. Based on our finding
of increased ACE mRNA and protein expression within
the IEL, we then hypothesized that ACE may also have
a relevant role in the modulation of EC apoptosis within
the gastrointestinal mucosa. Administration of the ACE-I
enalaprilat to SBS mice reversed the increase in EC apop-
tosis observed with SBS alone, bringing levels to that of
non-operated mice. Interestingly, this observed ACE-I-
associated decline in EC apoptosis was predominately in
the crypt region and lower one-third of the villi. Mor-
phologically, this decline in EC apoptosis was reflected in
a significant increase in crypt depth; whereas there was
relatively little change in total villus length. Crypt cell
apoptosis has been shown to progress quite differently
compared to apoptosis along the villi.30 This also sug-
gests that ACE may play a key role in the remodeling of
the crypt during the early phases of SBS adaptation. This
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location of EC apoptosis was different from the finding
of apoptosis in the villus tips, as seen with the normal
process of villus growth and in some models of intestinal
ischemia.39 Importantly, however, EC apoptosis in other
mouse models of intestinal injury as well as in other stud-
ies of SBS have been shown to predominate in the crypt
region.30,40 Thus it appears that different processes will
greatly affect the location of apoptosis along the crypt-
villus axis. The observed changes in weight loss—and
particularly the lower degree of weight loss in the SBS
+ ACE-I group may suggest an improvement in SBS
adaptation in the ACE-I treated group, although specific
absorption studies would need to be performed in future
studies to prove this. It was also interesting to note that
EC proliferation was also augmented in the SBS+ACE-I
group compared to the SBS group. Interestingly, ACE
may also demonstrate effects on proliferation, as well as
apoptosis.20 This ACE-I associated augmentation of EC
proliferation, may help to augment SBS adaptation, al-
though this will need future work to confirm.
The mechanism by which ACE-I affects apoptosis is
not fully understood. Several studies have shown a change
in lymphocyte cytokine expression with the use of ACE-
I. Schindler et al. investigated the in vitro synthesis of
TNF-α from human peripheral blood mononuclear cells
in the presence of the ACE-I captopril. These investiga-
tors showed a dose-dependent suppression of the synthe-
sis of TNF-α.41 Our group has previously showed that
IEL-derived TNF-α is increased after the creation of a
SBS model in mice.32 Our current study confirmed this
finding. Interestingly, we further observed a significant
decline in TNF-α with ACE-I. To further address the pos-
sibility of a TNF-α-dependent mechanism for the reduc-
tion of apoptosis with ACE-I, TNF-α−/− mice were used.
TNF-α−/− mice subjected to a Sham (transection) oper-
ation demonstrated no change in EC apoptotic rates with
or without the administration of the ACE-I enalaprilat.
This strongly suggests that ACE-mediated EC apoptosis
within the gastrointestinal tract is dependent on TNF-
α. It also suggests that the observed down-regulation in
TNF-α expression by enalaprilat could be a major mecha-
nism by which ACE-I mediates its anti-apoptotic action.
This effect of ACE-I on TNF-α expression has also been
shown by Fukuzawa et al. using blood mononuclear cells.
In their study the administration of captopril, delapril or
cilazapril was shown to inhibit the expression of TNF-
α.42 Ortiz et al. studied modulation of TNF-α expression
in a mouse model of pulmonary hypertension induced by
bleomycin. In this model there was an enhanced expres-
sion of TNF-α expression in the lung. Administration of
enalaprilat inhibited lung-TNF-α expression.43
ACE may work via the renin-angiotensin-system by
producing angiotensin II (ANG II). Wang et al. found
that ANG II was a potent inducer of apoptosis in alveolar
EC.44 It has been shown that ANG II acts through ANG II
type 1 and type 2 receptors.21 Although variable responses
may be seen in different tissues, type 1 receptors can
mediate the effects of smooth muscle cell proliferation and
growth.20,45 Others have also associated type 1 receptors
are also important mediators for apoptosis, although the
type of mediation may vary with different tissues. In
vascular smooth muscles cells, apoptosis was significantly
reduced in ANG II type 1a knockout mice.46 Conversely,
others have shown that the type 1a receptor is needed for
the mediation of alveolar EC apoptosis.47 Type 2 receptors
may enhance cell differentiation48 as well as stimulate
apoptosis.49 In our study we found that administration
of enalaprilat to SBS mice had led to a significant decline
in types 1b and 2 receptors, as well as a large, but non-
significant decline in the type 1a receptor. This may imply
that ACE mediation of EC apoptosis, and its prevention
with enalaprilat, is via a modulation of the expression
of ANG II receptors. Further assessment of this pathway
will be needed in the future to confirm this observation.
ACE may be expressed by both IEL (as observed in our
current study) as well as by EC, themselves.50 Although
there was a marked increase in ACE expression by IEL
in our SBS model, future studies will need to be done to
better define the amount of apoptosis mediated by IEL-
derived versus EC-derived ACE in the modulation of EC
apoptosis following SBS formation.
Another signaling pathway for EC apoptosis is via
the Fas/Fas ligand (FasL) system.51 Wang et al. showed
that activation of Fas stimulates alveolar EC to synthe-
size ANG II de novo.44 Moreover, the autocrine synthesis
of ANG II was found to be required for the induction
of apoptosis by Fas. Apoptosis could be abrogated by
ANG receptor antagonists or other blockers of ANG II
function. In our study, we did not find any significant
changes in Fas or FasL mRNA expression after bowel re-
section. Additionally, ACE-I administration after bowel
resection did not lead to any significant change in either
Fas, or FasL expression. These results are supported by
work from Knott et al. and a study from Tang et al.52,53
Both of these investigators reported that there were no
significant changes in Fas and FasL after bowel resection.
These results may suggest that Fas/FasL extrinsic pathway
is not involved in this SBS associated EC apoptosis.
The intrinsic pathway via the Bcl-2 family of proteins
have been well studied and found to play an important
role in the SBS related EC apoptosis.52–55 An increase
in intestinal bax (pro-apoptotic gene) expression and a
decrease in bcl-2 (anti-apoptotic gene) were found in a
mouse SBS model.55,56 Interestingly, the bcl-2 family of
proteins appears to be another mediator of apoptosis by
the RAS.46,57–60 Studies have identified a link between
ANGII signaling and apoptosis through this family of
proteins,57–61 including a decrease in the bcl-2: bax pro-
tein ratio in other systems. Whether IEL-derived ACE
mediates apoptosis via the intrinsic pathway, including
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changes in the bcl-2 family, will be important areas for
future investigations.
Conclusion
In conclusion, SBS was associated with a previously
undescribed expression of ACE by intestinal IEL. An-
other novel finding was that administration of the ACE-
I enalaprilat reversed the increase in SBS-associated EC
apoptosis; suggesting that, as observed in cardiac and
pulmonary tissue, ACE-I may have a similar action on
intestinal epithelial cells. Possible anti-apoptotic mecha-
nisms of the ACE-I enalaprilat in the intestinal tract may
be through RAS via suppression of TNF-α expression.
It is potentially possible that SBS patients may benefit
from the use of ACE-I, via a reduction of the apoptotic
rate—thus facilitating the degree of adaptation. Future
investigation will hopefully offer greater insight into the
action of ACE on the gastrointestinal mucosa.
Acknowledgments
Supported by National Institute of Health, USA
(AI44076-06), Novartis Stiftung Schweiz, Swiss National
Foundation, and Swiss Society of Pediatric Surgery. This
research was also supported (in part) by the National In-
stitutes of Health through the University of Michigan’s
Cancer Center Support Grant (5 P30 CA46592); with the
use of the Flow Cytometry Facility.
References
1. Ray EC, Avissar NE, Sax HC. Growth factor regulation of
enterocyte nutrient transport during intestinal adaptation. Am
J Surg 2002; 183: 361–371.
2. Westergaard H. Short bowel syndrome. Seminars in Gastroin-
testinal Disease 2002; 13: 210–220.
3. Vanderhoof JA, Langnas AN, Pinch LW, Thompson JS, Kauf-
man SS. Short bowel syndrome. J Pediatr Gastroenterol Nutr
1992; 14: 359–370.
4. Petersen Y, Burrin D, Sangild P. GLP-2 has differential effects
on small intestine growth and function in fetal and neonatal
pigs. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1986–
R1993.
5. Stern LE, Erwin CR, O’Brien DP, Huang F, Warner BW.
Epidermal growth factor is critical for intestinal adaptation
following small bowel resection. Microsc Res Tech 2000; 51:
138–148.
6. Thiesen A, Wild G, Tappenden K, et al. The locally acting glu-
cocorticosteroid budesonide enhances intestinal sugar uptake
following intestinal resection in rats. Gut 2003; 52: 252–259.
7. Sukhotnik I, Lerner A, Sabo E, et al. Effects of enteral arginine
supplementation on the structural intestinal adaptation in a
rat model of short bowel syndrome. Dig Dis Sci 2003; 48:
1346–1351.
8. O’Brien DP, Nelson LA, Kemp CJ, et al. Intestinal permeabil-
ity and bacterial translocation are uncoupled after small bowel
resection. J Pediatr Surg 2002; 37: 390–394.
9. Welters CF, Dejong CH, Deutz NE, Heineman E. Intestinal
adaptation in short bowel syndrome. ANZ J Surg 2002; 72:
229–236.
10. Falcone RA, Jr, Shin CE, Erwin CR, Warner B. The adaptive
intestinal response to massive enterectomy is preserved in c-
SRC-deficient mice. J Pediatr Surg 1999; 34: 800–804.
11. Klein RM, McKenzie JC. The role of cell renewal in the on-
togeny of the intestine. II. Regulation of cell proliferation in
adult, fetal, and neonatal intestine. J Pediatr Gastroenterol Nutr
1983; 2: 204–228.
12. Sham J, Martin G, Meddings JB, Sigalet DL. Epidermal
growth factor improves nutritional outcome in a rat model
of short bowel syndrome. J Pediatr Surg 2002; 37: 765–769.
13. Gillingham MB, Dahly EM, Carey HV, Clark MD, Kritsch
KR, Ney DM. Differential jejunal and colonic adaptation due
to resection and IGF-I in parenterally fed rats. Am J Physiol—
Gastrointest Liver Physiol 2000; 278: G700–G709.
14. Yang H, Wildhaber BE, Teitelbaum DH. 2003 Harry M.
Vars Research Award. Keratinocyte growth factor improves
epithelial function after massive small bowel resection. JPEN
J Parenter Enteral Nutr 2003; 27: 198–206; discussion 206–
207.
15. Tappenden K, Albin D, Bartholome A, Mangian H. Glucagon-
like peptide-2 and short-chain fatty acids: A new twist to an
old story. J Nutr 2003; 133: 3717–7320.
16. Chen Y, Chou K, Fuchs E, Havran W, Boismenu R. Protection
of the intestinal mucosa by intraepithelial gamma delta T cells.
Proc Natl Aacd Sci USA 2002; 99: 14338–14343.
17. Yang H, Antony PA, Wildhaber BE, Teitelbaum DH. In-
testinal intraepithelial lymphocyte gammadelta-T cell-derived
keratinocyte growth factor modulates epithelial growth in the
mouse. J Immunol 2004; 172: 4151–4158.
18. Wildhaber B, Yang H, Coran A, Teitelbaum D. Gene alteration
of intestinal intraepithelial lymphocytes in response to massive
small bowel resection. Ped Surg Int 2003; 19: 310–315.
19. Wang R, Zagariya A, Ibarra-Sunga O, et al. Angiotensin II
induces apoptosis in human and rat alveolar epithelial cells.
Am J Physiol 1999; 276: L885–L889.
20. Siragy HM. AT(1) and AT(2) receptors in the kidney: Role in
disease and treatment. Am J Kidney Dis 2000; 36: S4–S9.
21. Schiffrin EL. Vascular and cardiac benefits of angiotensin re-
ceptor blockers. Am J Med 2002; 113: 409–418.
22. Ward PE, Sheridan MA, Hammon KJ, Erdos EG. Angiotensin
I converting enzyme (kininase II) of the brush border of human
and swine intestine. Biochem Pharmacol 1980; 29: 1525–1529.
23. Defendini R, Zimmerman EA, Weare JA, Alhenc-Gelas F,
Erdos EG. Angiotensin-converting enzyme in epithelial and
neuroepithelial cells. Neuroendocrinology 1983; 37: 32–40.
24. Erickson RH, Suzuki Y, Sedlmayer A, Song IS, Kim YS. Rat in-
testinal angiotensin-converting enzyme: purification, proper-
ties, expression, and function. Am J Physiol 1992; 263: G466–
G473.
25. Danilov SM, Faerman AI, Printseva O, Martynov AV, Sakharov
I, Trakht IN. Immunohistochemical study of angiotensin-
converting enzyme in human tissues using monoclonal an-
tibodies. Histochemistry 1987; 87: 487–490.
26. Tamura K, Yokoyama N, Sumida Y, et al. Tissue-specific
changes of type 1 angiotensin II receptor and angiotensin-
converting enzyme mRNA in angiotensinogen gene-knockout
mice. J Endocrinol 1999; 160: 401–408.
27. Skidgel RA, Erdos EG. Angiotensin I converting enzyme. Adv
Exp Med Biol 1989; 247A: 25–28.
1314 Apoptosis · Vol 10 · No 6 · 2005
IEL-derived ACE modulates intestinal EC apoptosis
28. Helmrath MA, VanderKolk WE, Can G, Erwin CR, Warner
BW. Intestinal adaptation following massive small bowel re-
section in the mouse. J Am Coll Surg 1996; 183: 441–449.
29. Wilkins HR, Ohneda K, Keku TO, et al. Reduction of spon-
taneous and irradiation-induced apoptosis in small intestine of
IGF-I transgenic mice. Am J Physiol Gastrointest Liver Physiol
2002; 283: G457–G464.
30. Marshman E, Ottewell P, Potten C, Watson A. Caspase acti-
vation during spontaneous and radiationinduced apoptosis in
the murine intestine. J Pathol 2001; 195: 285–292.
31. Kiristioglu I, Teitelbaum DH. Alteration of the intestinal
intraepithelial lymphocytes during total parenteral nutrition.
J Surg Res 1998; 79: 91–96.
32. Yang H, Fan Y, Finaly R, Teitelbaum DH. Alteration of in-
testinal intraepithelial lymphocytes after massive small bowel
resection. J Surg Res 2003; 110: 276–286.
33. Yang H, Wildhaber B, Tazuke Y, Teitelbaum DH. 2002 Harry
M. Vars Research Award. Keratinocyte growth factor stimu-
lates the recovery of epithelial structure and function in a
mouse model of total parenteral nutrition. JPEN J Parenter
Enteral Nutr 2002; 26: 333–340; discussion 340–341.
34. Akbar AN. Life (and death) in the Fas lane [comment]. Gut
1998; 43: 5–6.
35. Odaka C, Mizuochi T. Angiotensin-converting enzyme in-
hibitor captopril prevents activation-induced apoptosis by in-
terfering with T cell activation signals. Clin Exp Immunol 2000;
121: 515–522.
36. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. An-
giotensin I-converting enzyme in human circulating mononu-
clear cells: Genetic polymorphism of expression in T-
lymphocytes. Biochem J 1993; 290: 33–40.
37. Wang R, Ramos C, Joshi I, Zagariya A, Pardo A, Selman
M, Uhal BD. Human lung myofibroblast-derived inducers of
alveolar epithelial apoptosis identified as angiotensin peptides.
Am J Physiol 1999; 277: L1158–L1164.
38. Yu G, Liang X, Xie X, Su M, Zhao S. Diverse effects of
chronic treatment with losartan, fosinopril, and amlodipine on
apoptosis, angiotensin II in the left ventricle of hypertensive
rats. Int J Cardiol 2001; 81: 123–129; discussion 129–130.
39. Coopersmith CM, D OD, Gordon JI. Bcl-2 inhibits ischemia-
reperfusion-induced apoptosis in the intestinal epithelium of
transgenic mice. Am J Physiol 1999; 276: G677–G686.
40. Jarboe M, Juno R, Bernal N, Knott A, Zhang Y, Erwin C,
Warner B. Bax deficiency rescues resection-induced entero-
cyte apoptosis in mice with perturbed EGF receptor function.
Surgery 2004; 136: 121–126.
41. Schindler R, Dinarello C, Koch K. Angiotensin-converting-
enzyme inhibitors suppress synthesis of tumour necrosis factor
and interleukin 1 by human peripheral blood mononuclear
cells. Cytokine 1995; 7: 526–533.
42. Fukuzawa M, Satoh J, Sagara M, et al. Angiotensin convert-
ing enzyme inhibitors suppress production of tumor necrosis
factor-alpha in vitro and in vivo. Immunopharmacology 1997; 36:
49–55.
43. Ortiz LA, Champion HC, Lasky JA, et al. Enalapril pro-
tects mice from pulmonary hypertension by inhibiting TNF-
mediated activation of NF-kappaB and AP-1. Am J Physiol
Lung Cell Mol Physiol 2002; 282: L1209–L1221.
44. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal B. Ab-
rogation of bleomycin-induced epithelial apoptosis and lung
fibrosis by captopril or by a caspase inhibitor. Am J Physiol
Lung Cell Mol Physiol 2000; 279: L143–L151.
45. Horiuchi M, Akishita M, Dzau V. Recent progress in an-
giotensin II type 2 receptor research in the cardiovascular sys-
tem. Hypertension 1999; 33: 613–621.
46. Suzuki J, Iwai M, Nakagami H, et al. Role of angiotensin
II-regulated apoptosis through distinct AT1 and AT2 recep-
tors in neointimal formation. Circulation 2002; 106: 847–
852.
47. Li X, Rayford H, Uhal BD. Essential roles for angiotensin re-
ceptor AT1a in bleomycin-induced apoptosis and lung fibrosis
in mice. Am J Pathol 2003; 163: 2523–2530.
48. Sabri A, Levy B, Poitevin P, et al. Differential roles of AT1
and AT2 receptor subtypes in vascular trophic and phenotypic
changes in response to stimulation with angiotensin II. Arte-
rioscler Thromb Vasc Biol 1997; 17: 257–264.
49. Schiffrin E. Reactivity of small blood vessels in hypertension:
relation with structural changes. State of the art lecture. Hy-
pertension 1992; 19: 1–9.
50. Naim HY. Human small intestinal angiotensin-converting
enzyme: intracellular transport, secretion and glycosylation.
Biochem J 1993; 296(Pt 3): 607–615.
51. Abreu-Martin MT, Palladino AA, Faris M, Carramanzana NM,
Nel AE, Targan SR. Fas activates the JNK pathway in human
colonic epithelial cells: Lack of a direct role in apoptosis. Am J
Physiol 1999; 276: G599–G605.
52. Knott AW, O’Brien DP, Juno RJ, et al. Enterocyte apoptosis
after enterectomy in mice is activated independent of the ex-
trinsic death receptor pathway. Am J Physiol—Gastrointest Liver
Physiol 2003; 285: G404–G413.
53. Tang Y, Swartz-Basile D, Swietlicki E, Yi L, Rubin D, Levin
M. Bax is required for resection-induced changes in apoptosis,
proliferation, and members of the extrinsic cell death path-
ways. Gastroenterology 2004; 126: 220–225.
54. Stern LE, Falcone RA, Jr, Huang F, Kemp CJ, Erwin CR,
Warner BW. Epidermal growth factor alters the bax:bcl-w
ratio following massive small bowel resection. J Surg Res 2000;
91: 38–42.
55. Stern LE, Huang F, Kemp CJ, Falcone RA, Jr, Erwin CR,
Warner BW. Bax is required for increased enterocyte apoptosis
after massive small bowel resection. Surgery 2000; 128: 165–
170.
56. Stern LE, Falcone RA, Jr, Kemp CJ, Stuart LA, Erwin CR,
Warner BW. Effect of massive small bowel resection on the
Bax/Bcl-w ratio and enterocyte apoptosis. J Gastrointest Surg
2000; 4: 93–100.
57. Leri A, Claudio P, Li Q, et al. Stretch-mediated release of
angiotensin II induces myocyte apoptosis by activating p53
that enhances the local renin-angiotensin system and decreases
the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 1998;
101: 1326–1331.
58. Abbate A, Biondi-Zoccai G, Baldi A. Pathophysiologic role
of myocardial apoptosis in post-infarction left ventricular re-
modeling. J Cell Physiol 2002; 193: 145–151.
59. Kobara M, Tatsumi T, Kambayashi D, et al. Effects of ACE in-
hibition on myocardial apoptosis in an ischemia-reperfusion
rat heart model. J Cardiovasc Pharmacol 2003; 41: 880–
885.
60. Pang J, Xu R, Xu X, et al. Hexarelin protects rat cardiomy-
ocytes from angiotensin II-induced apoptosis in vitro. Am J
Physiol Heart Circ Physiol 2004; 286: H1063–H1067.
61. Kumar D, Zimpelmann J, Robertson S, Burns K. Tubular
and interstitial cell apoptosis in the streptozotocin-diabetic
rat kidney. Nephron Exp Nephrol 2004; 96: e77–e79.
Apoptosis · Vol 10 · No 6 · 2005 1315
